持续病毒学应答可以降低肝硬化和肝病并发症的发生，降低肝癌(肝细胞性癌)和死亡的发生率。
Sustained virologic response can result in decreased cirrhosis and complications of liver disease, decreased rates of liver cancer (hepatocellular carcinoma), and decreased mortality.
应用三联疗法的患者中，超过70%的患者能够达到持续病毒学应答，同时对难治性基因型患者也能获得很好的疗效。
This will comprise of direct antiviral drugs such as protease inhibitors along with peg-Interferon and ribavirin. This can provide a sustained virological response in over 70% of patients.
这类患者出现持续病毒学应答(SVR)的机率很高——大概是70%到80%，且无治疗的禁忌症，是非常好的治疗对象。
These patients have a high likelihood of SVR (Sustained Virological Response) - probably 70-80% - and in the absence of any contraindications of therapy they are very good candidates.
持续性病毒学应答的最佳指标是较低的治疗前血清hbvDNA滴度和较高的谷丙转氨酶(ALT)水平。
The best indicators of sustained virologic response are low pre-treatment serum HBV DNA titers and elevated alanine aminotransferase (ALT) levels.
当受试者完成治疗后病毒学应答仍在持续，说明丙型肝炎病毒感染已获治愈。
When a person sustains a virologic response after completing treatment, this suggests that HCV infection has been cured.
在两项试验中，持续的病毒学应答率为79%和80%，相比标准治疗方案，即长效干扰素联合利巴韦林的应答率50%更高。
The sustained virologic response rate was 79% and 80% in two studies, which was higher than the response rate of 50% with the standard of care with peginterferon plus ribavirin.
在两项试验中，持续的病毒学应答率为79%和80%，相比标准治疗方案，即长效干扰素联合利巴韦林的应答率50%更高。
The sustained virologic response rate was 79% and 80% in two studies, which was higher than the response rate of 50% with the standard of care with peginterferon plus ribavirin.
应用推荐